Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trials

Irina Ghislain; Efstathios Zikos; Corneel Coens; Chantal Quinten; Vasiliki Balta; Konstantinos Tryfonidis; Martine Piccart; Dimitrios Zardavas; Eva Nagele; Vesna Bjelic-Radisic; Fatima Cardoso; Mirjam A. G. Sprangers; Galina Velikova; Andrew Bottomley

doi:https://doi.org/10.1016/S1470-2045(16)30099-7

Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trials

Irina Ghislain, Efstathios Zikos, Corneel Coens, Chantal Quinten, Vasiliki Balta, Konstantinos Tryfonidis, Martine Piccart, Dimitrios Zardavas, Eva Nagele, Vesna Bjelic-Radisic, Fatima Cardoso, Mirjam A. G. Sprangers, Galina Velikova, Andrew Bottomley

Research output: Contribution to journal › Review article › Academic › peer-review

78 Citations (Scopus)

Abstract

Breast cancer is the leading cause of cancer death among women worldwide, and increasingly, randomised controlled trials of this disease are measuring the health-related quality of life of these patients. In this systematic Review, we assess the adequacy of methods used to report health-related quality of life (HRQOL) from 49 eligible randomised controlled trials of advanced breast cancer. We compare our findings with those from the literature to investigate whether the standard of HRQOL reporting in this field has changed. We conclude that the overall reporting of HRQOL has improved, but some crucial aspects remain problematic, such as the absence of HRQOL research hypotheses and the overemphasis on statistical rather than clinical significance. Additionally, new challenges are arising with the emergence of novel treatments and the advent of personalised medicine, and improved HRQOL tools are required to cover the range of side-effects of newer therapies

Original language	English
Pages (from-to)	e294-e304
Journal	lancet oncology
Volume	17
Issue number	7
DOIs	https://doi.org/10.1016/S1470-2045(16)30099-7
Publication status	Published - 2016

Access to Document

https://doi.org/10.1016/S1470-2045(16)30099-7

Cite this

Ghislain, I., Zikos, E., Coens, C., Quinten, C., Balta, V., Tryfonidis, K., Piccart, M., Zardavas, D., Nagele, E., Bjelic-Radisic, V., Cardoso, F., Sprangers, M. A. G., Velikova, G., & Bottomley, A. (2016). Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trials. lancet oncology, 17(7), e294-e304. https://doi.org/10.1016/S1470-2045(16)30099-7

@article{4e6332cc26034f2e8821e0b0be8955eb,

title = "Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trials",

abstract = "Breast cancer is the leading cause of cancer death among women worldwide, and increasingly, randomised controlled trials of this disease are measuring the health-related quality of life of these patients. In this systematic Review, we assess the adequacy of methods used to report health-related quality of life (HRQOL) from 49 eligible randomised controlled trials of advanced breast cancer. We compare our findings with those from the literature to investigate whether the standard of HRQOL reporting in this field has changed. We conclude that the overall reporting of HRQOL has improved, but some crucial aspects remain problematic, such as the absence of HRQOL research hypotheses and the overemphasis on statistical rather than clinical significance. Additionally, new challenges are arising with the emergence of novel treatments and the advent of personalised medicine, and improved HRQOL tools are required to cover the range of side-effects of newer therapies",

author = "Irina Ghislain and Efstathios Zikos and Corneel Coens and Chantal Quinten and Vasiliki Balta and Konstantinos Tryfonidis and Martine Piccart and Dimitrios Zardavas and Eva Nagele and Vesna Bjelic-Radisic and Fatima Cardoso and Sprangers, {Mirjam A. G.} and Galina Velikova and Andrew Bottomley",

year = "2016",

doi = "https://doi.org/10.1016/S1470-2045(16)30099-7",

language = "English",

volume = "17",

pages = "e294--e304",

journal = "lancet oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "7",

}

Ghislain, I, Zikos, E, Coens, C, Quinten, C, Balta, V, Tryfonidis, K, Piccart, M, Zardavas, D, Nagele, E, Bjelic-Radisic, V, Cardoso, F, Sprangers, MAG, Velikova, G & Bottomley, A 2016, 'Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trials', lancet oncology, vol. 17, no. 7, pp. e294-e304. https://doi.org/10.1016/S1470-2045(16)30099-7

TY - JOUR

T1 - Health-related quality of life in locally advanced and metastatic breast cancer: methodological and clinical issues in randomised controlled trials

AU - Ghislain, Irina

AU - Zikos, Efstathios

AU - Coens, Corneel

AU - Quinten, Chantal

AU - Balta, Vasiliki

AU - Tryfonidis, Konstantinos

AU - Piccart, Martine

AU - Zardavas, Dimitrios

AU - Nagele, Eva

AU - Bjelic-Radisic, Vesna

AU - Cardoso, Fatima

AU - Sprangers, Mirjam A. G.

AU - Velikova, Galina

AU - Bottomley, Andrew

PY - 2016

Y1 - 2016

N2 - Breast cancer is the leading cause of cancer death among women worldwide, and increasingly, randomised controlled trials of this disease are measuring the health-related quality of life of these patients. In this systematic Review, we assess the adequacy of methods used to report health-related quality of life (HRQOL) from 49 eligible randomised controlled trials of advanced breast cancer. We compare our findings with those from the literature to investigate whether the standard of HRQOL reporting in this field has changed. We conclude that the overall reporting of HRQOL has improved, but some crucial aspects remain problematic, such as the absence of HRQOL research hypotheses and the overemphasis on statistical rather than clinical significance. Additionally, new challenges are arising with the emergence of novel treatments and the advent of personalised medicine, and improved HRQOL tools are required to cover the range of side-effects of newer therapies

AB - Breast cancer is the leading cause of cancer death among women worldwide, and increasingly, randomised controlled trials of this disease are measuring the health-related quality of life of these patients. In this systematic Review, we assess the adequacy of methods used to report health-related quality of life (HRQOL) from 49 eligible randomised controlled trials of advanced breast cancer. We compare our findings with those from the literature to investigate whether the standard of HRQOL reporting in this field has changed. We conclude that the overall reporting of HRQOL has improved, but some crucial aspects remain problematic, such as the absence of HRQOL research hypotheses and the overemphasis on statistical rather than clinical significance. Additionally, new challenges are arising with the emergence of novel treatments and the advent of personalised medicine, and improved HRQOL tools are required to cover the range of side-effects of newer therapies

U2 - https://doi.org/10.1016/S1470-2045(16)30099-7

DO - https://doi.org/10.1016/S1470-2045(16)30099-7

M3 - Review article

C2 - 27396647

SN - 1470-2045

VL - 17

SP - e294-e304

JO - lancet oncology

JF - lancet oncology

IS - 7

ER -